BOSTON, Oct. 30, 2020 /PRNewswire/ -- Stealth
BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology
company focused on the discovery, development and commercialization
of novel therapies for diseases involving mitochondrial
dysfunction, today announced that it will report third quarter 2020
financial results on Thursday, November 5,
2020, before the market opens.
Management will host a conference call at 8:30 am ET that day to discuss the financial
results and provide a general business update. The call can be
accessed by dialing (877)-407-0989 (domestic) or (201)-389-0921
(international) and referencing conference ID 13710878. A live
audio webcast of the event can be accessed by visiting the
Investors & News section of Stealth's Investor website,
https://investor.stealthbt.com/. A replay of the webcast will be
archived on Stealth's website for 30 days following the event.
About Stealth
We are a clinical-stage biotechnology company focused on the
discovery, development and commercialization of novel therapies for
diseases involving mitochondrial dysfunction. Mitochondria, found
in nearly every cell in the body, are the body's main source of
energy production and are critical for normal organ function.
Dysfunctional mitochondria characterize a number of rare genetic
diseases and are involved in many common age-related diseases,
typically involving organ systems with high energy demands such as
the heart, the eye, and the brain. We believe our lead product
candidate, elamipretide, has the potential to treat both rare
metabolic cardiomyopathies, such as Barth, Duchenne and Becker
muscular dystrophies and Friedreich's ataxia, rare mitochondrial
diseases entailing nuclear DNA mutations, such as POLG-related
disorders, as well as ophthalmic diseases entailing mitochondrial
dysfunction, such as dry age-related macular degeneration and
Leber's hereditary optic neuropathy. We are evaluating our
second-generation clinical stage candidate, SBT-272, for rare
neurodegenerative disease indications following promising
preclinical data in amyotrophic lateral sclerosis, or ALS. We have
optimized our discovery platform to identify novel
mitochondria-targeted compounds, including SBT-259, the SBT-550
series of compounds, and other compounds which may be nominated as
therapeutic product candidates or utilized as scaffolds to deliver
other compounds to mitochondria.
Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-report-third-quarter-2020-financial-results-on-thursday-november-5-2020-301164006.html
SOURCE Stealth BioTherapeutics Inc.